Last reviewed · How we verify
Solu-medrol or placebo administration
Solu-Medrol (methylprednisolone sodium succinate) is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting pro-inflammatory cytokine production and immune cell activation.
Solu-Medrol (methylprednisolone sodium succinate) is a corticosteroid that suppresses the immune system and reduces inflammation by inhibiting pro-inflammatory cytokine production and immune cell activation. Used for Acute inflammatory and autoimmune conditions (e.g., multiple sclerosis exacerbations, rheumatoid arthritis flares), Severe allergic reactions, Organ transplant rejection prophylaxis.
At a glance
| Generic name | Solu-medrol or placebo administration |
|---|---|
| Also known as | Solu-medrol 500mg IV BE145214, Solu-medrol 500mg IV H02AB04, Solu-medrol 500mg IV SUB14562MIG, Solu-medrol 500mg IV 277S102F12 |
| Sponsor | Erasme University Hospital |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Inflammation, Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Methylprednisolone is a synthetic glucocorticoid that binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene transcription. This results in decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and reduced migration and activation of immune cells. The intravenous formulation (Solu-Medrol) provides rapid systemic anti-inflammatory and immunosuppressive effects.
Approved indications
- Acute inflammatory and autoimmune conditions (e.g., multiple sclerosis exacerbations, rheumatoid arthritis flares)
- Severe allergic reactions
- Organ transplant rejection prophylaxis
- Cerebral edema
- Spinal cord injury (acute phase)
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia
- Mood changes (euphoria, anxiety)
- Infection risk (immunosuppression)
- Hypokalemia
- Gastrointestinal upset
Key clinical trials
- TReatment for ImmUne Mediated PathopHysiology (PHASE2)
- GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (PHASE2, PHASE3)
- GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease (PHASE3)
- Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement (PHASE2)
- Steroids and Microcirculation In Cardiac Surgery (PHASE4)
- Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA) (PHASE4)
- Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis (PHASE2, PHASE3)
- Glucocorticoid Therapy Impact on the Inflammatory Response and Clinical Evolution in Patients With Severe Bronchiolitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: